Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir disoproxil fumarate - Gilead Sciences

Drug Profile

Tenofovir disoproxil fumarate - Gilead Sciences

Alternative Names: Bis-POC-PMPA; GSK548470; PMPA-prodrug; Tenofovir DF; Tenozet; Viread

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; GlaxoSmithKline; University of California
  • Class Antiretrovirals; Antivirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; HIV infections

Most Recent Events

  • 13 Sep 2021 Biomarkers information updated
  • 06 Jul 2021 Arbutus Biopharma and Antios Therapeutics plans to initiate a Phase IIa ANTT201 clinical trial cohort in the second half of 2021
  • 23 Jun 2021 Long-term efficacy and safety data from a phase III trial in Hepatitis B presented at the The International Liver Congress 2021 (ILC-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top